North America Influenza Vaccine Market Size & Outlook
- Pharmaceuticals
- Vaccines
- Influenza Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the influenza vaccine market
North America influenza vaccine market highlights
- The North America influenza vaccine market generated a revenue of USD 4,200.0 million in 2023.
- The market is expected to grow at a CAGR of 6.5% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 4,200.0 million |
| Market revenue in 2030 | USD 6,482.2 million |
| Growth rate | 6.5% (CAGR from 2024 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, North America region accounted for 53.1% of the global influenza vaccine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,360.7 million by 2030.
North America leads the global influenza vaccine market in terms of revenue generation, owing to the launch of effective products along with technologically advanced vaccine production facilities across the region. In addition, the increasing prevalence of influenza infection in the U.S. & Canada and the growing sales of influenza vaccines in the region are also expected to fuel the market growth.
No credit card required*
Publish Date: Dec 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Viatris Inc | View profile | 38,000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | www.viatris.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| Emergent BioSolutions Inc | View profile | 1,600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | www.emergentbiosolutions.com |
| Vaxess Technologies | View profile | 51-100 | Cambridge, Massachusetts, United States, North America | www.vaxess.com |
| Osivax | View profile | 11-50 | Lyon, Rhone-Alpes, France, Europe | www.osivax.com/ |
North America Influenza Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Influenza Vaccine Market Outlook will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 97.76% in 2023.
Horizon Databook has segmented the North America influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
North America leads the global influenza vaccine market in terms of revenue generation, owing to the launch of effective products along with technologically advanced vaccine production facilities across the region. In addition, the increasing prevalence of influenza infection in the U.S. & Canada and the growing sales of influenza vaccines in the region are also expected to fuel the market growth.
- North America Influenza Vaccine Market Vaccine Type Outlook (Revenue, USD Million , 2018-2030)
- Inactivated
- Live Attenuated
- North America Influenza Vaccine Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Quadrivalent
- Trivalent
- North America Influenza Vaccine Market Age Group Outlook (Revenue, USD Million , 2018-2030)
- Pediatric
- Adult
- North America Influenza Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2018-2030)
- Injection
- Nasal Spray
- North America Influenza Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Pharmacy
- Government & Institutional supply
- Other Distribution Channels
Reasons to subscribe to Influenza Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Influenza Vaccine Market Outlook databook
- Our clientele includes a mix of Influenza Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Influenza Vaccine Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Influenza Vaccine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
North America Influenza Vaccine Market, 2018-2030 (US$M)
North America influenza vaccine market statistics, by vaccine type, 2018-2030 (US$M)
